International Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Identifying Common Diagnostic Biomarkers and Therapeutic Targets between COPD and Sepsis: A Bioinformatics and Machine Learning Approach.","authors":"Xinyi Li, Yuyang Xiao, Meng Yang, Xupeng Zhang, Zhangchi Yuan, Zaiqiu Zhang, Hanyong Zhang, Lin Liu, Mingyi Zhao","doi":"10.2147/COPD.S510846","DOIUrl":"10.2147/COPD.S510846","url":null,"abstract":"<p><strong>Background: </strong>Evidence suggests a bidirectional association between chronic obstructive pulmonary disease (COPD) and sepsis, but the underlying mechanisms remain unclear. This study aimed to explore shared diagnostic genes, potential mechanisms, and the role of immune cells in the COPD-sepsis relationship using Mendelian randomization (MR) and bioinformatics approaches, while also identifying potential therapeutic drugs.</p><p><strong>Methods: </strong>Two-sample MR analysis was performed using genome-wide association data to assess genetically predicted COPD and sepsis. Immune cell-mediated effects were quantified using a two-way two-sample MR analysis. Differential expression gene (DEG) analysis and weighted gene co-expression network analysis (WGCNA) were used to identify common genes. Functional enrichment analyses were conducted to explore the biological roles of these genes. LASSO and SVM-RFE algorithms identified shared diagnostic genes, which were evaluated using receiver operating characteristic (ROC) curves. Immune cell infiltration was analyzed with CIBERSORT, while transcription factor (TF) and miRNA networks were constructed using NetworkAnalyst. Drug predictions were made using DSigDB, and molecular docking validated potential drugs.</p><p><strong>Results: </strong>Three immune cell types were identified as mediators between COPD and sepsis, with genetically predicted effects mediated by these cells at rates of 6.5%, 12.8%, and 3.9%. A total of 33 overlapping genes were identified, and AIM2 and RNF125 were highlighted as key diagnostic genes. Immune infiltration analysis revealed dysregulated monocyte, macrophage, plasma, and dendritic cells. Regulatory network analysis identified nine key co-regulators. Ten potential drug targets were identified, with seven validated via molecular docking.</p><p><strong>Conclusion: </strong>AIM2 and RNF125 may serve as diagnostic biomarkers, and identified immune cell subsets could mediate the COPD-sepsis connection, offering insights into potential therapeutic targets.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1761-1786"},"PeriodicalIF":2.7,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness of Triple Extrafine Fixed-Dose Combination with Beclomethasone/Formoterol/Glycopyrronium on Symptoms and Lung Function in COPD: A Systematic Review and Meta-Analysis.","authors":"Paola Rogliani, Gian Marco Manzetti, Mario Cazzola, Luigino Calzetta","doi":"10.2147/COPD.S511334","DOIUrl":"10.2147/COPD.S511334","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic obstructive pulmonary disease (COPD) is a significant global health issue characterized by persistent airflow limitation and inflammation. Triple fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS), long-acting β2-agonists (LABA), and long-acting muscarinic antagonists (LAMA) show promise by potentially enhancing bronchodilation and anti-inflammatory effects. Although randomized controlled trials (RCTs) provide efficacy data, they may not fully represent real-world clinical practice, highlighting the value of real-world evidence (RWE).</p><p><strong>Methods: </strong>This study conducted a systematic review and meta-analysis of prospective observational multicenter studies to evaluate the real-world effectiveness of a triple extrafine FDC containing beclomethasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G) in moderate-to-severe COPD patients. Databases MEDLINE and SCOPUS were searched for relevant studies reporting on the COPD Assessment Test (CAT) score and forced expiratory volume in one second (FEV₁).</p><p><strong>Results: </strong>The meta-analysis included seven studies with 5952 patients, indicating high methodological quality with Newcastle-Ottawa Scale scores ≥7. Results showed significant improvement in CAT scores (-5.82 95% CI -7.61 - -4.03; P < 0.001) and FEV₁ (127 mL 95% CI 42-212; P < 0.001) for extrafine BDP/FF/G FDC compared to any prior treatments (ICS/LABA, ICS+LABA, LABA/LAMA, LABA+LAMA, multiple-inhaler triple therapy, single-inhaler triple therapy), exceeding minimal clinically important differences. Heterogeneity was significant, but Egger's test suggested no significant publication bias.</p><p><strong>Conclusion: </strong>The triple extrafine BDP/FF/G FDC effectively improves health status and lung function in real-world COPD patients, supporting its use as a viable therapeutic strategy. Further research should explore long-term outcomes and investigate specific patient subgroups to optimize individualized treatment approaches.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1723-1736"},"PeriodicalIF":2.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhaled Triple Therapy with Extrafine Single Inhaler Versus Multiple Devices in Chronic Obstructive Pulmonary Disease (TRIPOLI): A Post-Authorization Retrospective Study.","authors":"Eva Cabrera César, Javier López García, Daniel Enrique Vega Lizarazo, Miguel Benítez-Cano Gamonoso, Mercedes Segura Romero, Sara Sanchez Martín, Mónica I León Nieto, Diego González-Segura Alsina, José Luis Velasco Garrido","doi":"10.2147/COPD.S513351","DOIUrl":"10.2147/COPD.S513351","url":null,"abstract":"<p><strong>Background: </strong>Triple therapy significantly enhances both clinical and functional outcomes in patients with uncontrolled chronic obstructive pulmonary disease (COPD), even when they are already receiving treatment. However, it is often prescribed with multiple inhalers, which can affect adherence to treatment. The evidence on the effectiveness of extrafine single inhaler triple therapy (efSITT) compared to multiple inhalers triple therapy (MITT) in patients with moderate-to-severe COPD in the real-world setting is limited.</p><p><strong>Methods: </strong>TRIPOLI was a unicentric retrospective observational study that compared one year of efSITT with beclomethasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium with one year of MITT in terms of exacerbations, use of rescue medication, adherence, and lung function in patients with COPD.</p><p><strong>Results: </strong>A total of 71 patients were analyzed. The mean number of total and moderate exacerbations showed a significant reduction of 27.56% (p = 0.0043) and 29.56% (p = 0.0008), respectively, after efSITT. The percentage of patients with poor adherence decreased from 30.2% to 9.9% with efSITT and the proportion of patients with complete adherence increased from 55.8% to 81.7%. An improvement of 2.29% was described in mean forced expiratory volume in the first second (% pred). No differences were observed in the rate of pneumonia between the treatment with efSITT and MITT.</p><p><strong>Conclusion: </strong>The TRIPOLI study suggests that switching from MITT to efSITT might reduce exacerbations in patients with moderate-to-severe COPD, likely attributable to improved adherence in real-world settings.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1737-1747"},"PeriodicalIF":2.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Preserved Ratio Impaired Spirometry (PRISm) Based on Different Definitions in the Early COPD Cohort.","authors":"Cuiqiong Dai, Gaoying Tang, Huajing Yang, Fan Wu, Zhishan Deng, Youlan Zheng, Ningning Zhao, Lifei Lu, Qi Wan, Zihui Wang, Jieqi Peng, Xiaohui Wu, Kunning Zhou, Guannan Cai, Shan Xiao, Xiang Wen, Changli Yang, Shengtang Chen, Shuqing Yu, Ruiting Sun, Yumin Zhou, Pixin Ran","doi":"10.2147/COPD.S514181","DOIUrl":"10.2147/COPD.S514181","url":null,"abstract":"<p><strong>Background: </strong>Preserved ratio impaired spirometry (PRISm), which identifies a population at high risk for COPD, has drawn increasing attention. However, definitions for PRISm vary across studies, and researches comparing these definitions are limited.</p><p><strong>Objective: </strong>We aim to assess the agreement, the clinical features, and the prevalence of PRISm defined by restrictive spirometric pattern (RSP) method [that is forced vital capacity (FVC) method] versus forced expiratory volume in the first second (FEV₁) method and by fixed values versus the lower limit of normal (LLN).</p><p><strong>Methods: </strong>All 1862 participants from the ECOPD study underwent questionnaire investigation, spirometry, biphasic CT, and impulse oscillometry. Participants were categorized into control and two targeted groups (RSP fixed and PRISm fixed excluding RSP fixed) based on FVC and FEV₁ fixed definitions. Similar categorizations were conducted for RSP LLN versus PRISm LLN and PRISm fixed versus PRISm LLN. We assessed the agreement, the clinical features, and the prevalence of PRISm among these various definitions, repeating all analyses using Global Lung function Initiative (GLI) equation.</p><p><strong>Results: </strong>Significant overlap with merely moderate agreement (Kappa coefficient = 0.706, P value <0.001) existed between RSP fixed and PRISm fixed definitions. Participants identified as PRISm by both definitions exhibited lower lung function, higher airway reactance, and increased airway resistance compared to the control group. Similar findings were observed in RSP LLN versus PRISm LLN and PRISm fixed versus PRISm LLN. Our sensitivity analysis verified the consistency of these results. Furthermore, the prevalence of PRISm varied from 2.0% to 12.5% depending on the definitions and predicted equations, with the Chinese equation, LLN definition in Chinese equation and fixed definition in GLI equation yielding higher prevalence rates.</p><p><strong>Conclusion: </strong>Our findings highlight concerns about the comparability of studies and the interchangeability of various definitions and reference equations for PRISm.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1711-1722"},"PeriodicalIF":2.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12124300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cost-Effectiveness of a Personalised Early Warning Decision Support System (The COPDPredict™ System) to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease.","authors":"James A Hall, Alice M Turner, Eleni Gkini, Rajnikant Mehta, Monica Spiteri, Neil Patel, Sue Jowett","doi":"10.2147/COPD.S486309","DOIUrl":"10.2147/COPD.S486309","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic obstructive pulmonary disease (COPD) is a respiratory disease associated with significant morbidity, mortality, and healthcare burden. Many COPD patients are frequent exacerbators, which has a significant impact on patient prognosis. Prompt exacerbation management using a digital tool, COPDPredict™ may support COPD patients in identifying exacerbations earlier to reduce hospital admissions.</p><p><strong>Methods: </strong>Trial-based cost-utility and cost-effectiveness analyses from the UK National Health Service perspective compared the cost-effectiveness of COPDPredict™ with usual care for a COPD GOLD stage B and D cohort. A model-based analysis was also performed by extrapolating data from the trial to obtain the-cost-utility over a 5-year time horizon. The de-novo model was constructed using GOLD stages A-D as the health states.</p><p><strong>Results: </strong>The imputed trial-based analysis showed that at a willingness to pay £20,000 per quality-adjusted life-year (QALY), COPDPredict™ was 65% likely cost-effective in COPD B and D patients over 6-months with an incremental cost-effectiveness ratio (ICER) of £11,669/QALY (incremental cost +£238.16 (106.42), Incremental QALY +0.02 (0.012)). The results were robust to complete case analyses over 6- and 12-months. A similar ICER (£11,862/QALY) was obtained when performing model-based analysis over 5-years. Cost-effectiveness was sensitive to long-term effectiveness, cost parameters and alternative model structure, with expected value of information analyses suggesting a significant benefit from future research targeting the long-term effectiveness of the intervention.</p><p><strong>Conclusion: </strong>COPDPredict™ is potentially cost-effective for COPD B and D patients. However, the small samples sizes upon which the results were obtained warrant further investigation.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1693-1710"},"PeriodicalIF":2.7,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing Small Airways Dysfunction in COPD Patients in Real Life Under Fixed Triple Combination of Beclomethasone/Formoterol/Glycopyrronium: The MASCOT Real World Evidence Study.","authors":"Athena Gogali, Konstantinos Kostikas, Christos Kyriakopoulos, Dimitrios Potonos, Konstantinos Porpodis, Ioanna Tsiouprou, Evangelia Fouka, Stavros Tryfon, Efthymia Papadopoulou, Maria Kipourou, Konstantinos Katsoulis","doi":"10.2147/COPD.S513350","DOIUrl":"10.2147/COPD.S513350","url":null,"abstract":"<p><strong>Introduction: </strong>The efficacy of the fixed extrafine combination of beclomethasone/formoterol/glycopyrronium (BDP/FF/G 87/5/9 μg) has been evaluated in randomized controlled trials of patients with chronic obstructive pulmonary disease (COPD). However, only few data exist on its effectiveness on small airways dysfunction (SAD).</p><p><strong>Methods: </strong>The MASCOT (MAnaging Small airways dysfunction in COPD patients in real life on the fixed Triple combination of BDP/FF/G 87/5/9 μg pMDI) prospective observational study evaluated the effectiveness of this combination on SAD in a period of 4 weeks, after direct switch from long-acting β₂-agonists (LABA) and long-acting muscarinic antagonists (LAMA) in COPD patients with SAD (forced expiratory flow at 25-75% of the vital capacity, FEF25-75% <60% predicted). The primary endpoint was improvement in R5-19 in oscillometry; secondary endpoints included other oscillometry parameters, lung function and health status (COPD assessment test-CAT, Saint-George's Respiratory Questionnaire-SGRQ).</p><p><strong>Results: </strong>Between May 2022 and July 2023 we recruited 93 COPD patients (mean age 68.5 years, 82% men) with forced expiratory volume in 1 second (FEV₁, mean ± SD) 1.53 ± 0.47L (53.4 ± 14.5% predicted) and small airways dysfunction (FEF25-75% predicted 27.7 ± 15.4%). We observed statistically significant improvement in R5-19 between baseline (V1) and follow-up (V2) visits [median (IQR) V2 0.70 (0.41-1.10) vs V1 0.90 (0.60-1.83); mean change (95% CI) -0.49, -0.66 to -0.33 cmH₂O/L/sec, p < 0.0001). There were improvements in multiple parameters, including FEF25-75% (3.43, 1.20% to 5.66%, p = 0.0005), FEV₁ (0.142, 0.078 to 0.205 L, p < 0.0001) and RV/TLC (-6.09, -9.61% to -2,56% predicted, p < 0.0001), as well as improvement in CAT score -4.09 (-5.09 to -3.08) και SGRQ total score (-8.75, -11.58 to -5.93 points, p < 0.0001).</p><p><strong>Conclusion: </strong>Extrafine triple therapy improved SAD and spirometric parameters, leading to improvement in health status at 4 weeks. These results need to be confirmed in longer studies.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1651-1663"},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12108956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144163178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Apolipoprotein E in Predicting One-year Mortality in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.","authors":"Yuqun Li, Qilan Wu, Zhenxing Li, Yang Xiao, Liping Wei","doi":"10.2147/COPD.S512096","DOIUrl":"10.2147/COPD.S512096","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic obstructive pulmonary disease (COPD) is a serious disease with significantly higher mortality. Evidence suggests that there may be a co-relation between ApoE and the mortality risk in individuals who are diagnosed with COPD. This study sought to investigate the correlation between the levels of ApoE and all-cause mortality over one year in individuals who are diagnosed with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).</p><p><strong>Methods: </strong>In this study, we checked serum ApoE concentrations of AECOPD patients on admission and collected the patients' laboratory and clinical information. The co-relation between the concentration of ApoE and one year risk of all-cause mortality was analyzed by univariate, multivariate Cox regression and Subgroup analysis. Restricted Cubic Spline (RCS) were employed to illustrate the connection between ApoE levels and the hazard ratio (HR) for one-year total mortality rate.</p><p><strong>Results: </strong>Of the 449 participants who were enrolled, 358 patients were included in the study. The mean age was 76 (±9.46) years old, of which 65.92% were male. The body-mass index was 22.18 (±4.66). Of the participants, 24.86% were non-smokers, 54.75% were former smokers, and 20.39% were active smokers, with a smoking history of 28.68 (±20.43) years. The restricted cubic spline curve revealed that patients exhibiting ApoE concentrations exceeding the mean value of 41.50 mg/L faced a notably higher risk of mortality in comparison to individuals with lower levels. In univariate analysis, the HR was 2.663 (95% CI 1.533-4.627, P = 0.001), but in adjusted analyses, the HR was 2.103 (95% CI 1.19-3.716, P = 0.01).</p><p><strong>Conclusion: </strong>Elevated levels of ApoE were independently risk factor for one-year mortality in patients with AECOPD. Subgroup analyses revealed that the association was stronger in younger patients (<76 years) and male, as well as in those without comorbidities such as congestive heart failure or cerebrovascular disease. This suggests that ApoE may be a potential prognostic biomarker for AECOPD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1639-1650"},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12108998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144163183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Digoxin in Preventing Cigarette Smoke-Induced COPD via HIF-1α Inhibition in a Mouse Model.","authors":"Kedong Zhang, Feng Zhou, Caixia Zhu, Liang Yuan, Defu Li, Jian Wang, Wenju Lu","doi":"10.2147/COPD.S493856","DOIUrl":"10.2147/COPD.S493856","url":null,"abstract":"<p><strong>Purpose: </strong>Hypoxia-inducible factor-1α (HIF-1α) plays an important regulatory role in inflammatory and hypoxic diseases. Higher HIF-1α level was found in the lungs of chronic obstructive pulmonary disease (COPD) patients, however, its role in cigarette smoke (CS)-induced COPD has not been fully studied. Digoxin has been showed to inhibit HIF-1α translation and block HIF-1α activity and thus is often used as the HIF-1α inhibitor. Therefore, in the present study, we chose digoxin as the inhibitor to investigate whether HIF-1α contributes to the progression in a mouse model of COPD and possible mechanism.</p><p><strong>Methods: </strong>The COPD model was established by cigarette smoke (CS) exposed; animals were intragastrically treated with vehicle or different doses of digoxin (0.02 mg/kg and 0.1 mg/kg). COPD associated phenotypes such as pathological changes in lungs, inflammation, lung function and mucus secretion in airways were evaluated. Meanwhile, cigarette smoke extract (CSE) treated A549 cells were administrated with digoxin (50nM) or Smad3 inhibitor (S7959 100uM). Moreover, EMT associated markers together with HIF-1α/TGF-β1/Smad3 signaling pathway were detected both in vivo and in vitro.</p><p><strong>Results: </strong>The level of HIF-1α was significantly increased in lungs of COPD mice and CSE-exposed A549 cells, which was markedly suppressed by digoxin. Moreover, digoxin inhibited CS-induced inflammatory responses, lung function decline, and mucus hyper-secretion in COPD mouse model. In vitro studies, digoxin decreased CSE-induced pro-inflammatory cytokine release. Importantly, CS-induced or CSE-induced EMT and up-regulation of HIF-1α/TGF-β1/Smad pathway were inhibited by digoxin in vitro. Additionally, S7959 mitigated CSE-induced EMT in A549 cells.</p><p><strong>Conclusion: </strong>Digoxin can protect CS-induced COPD and prevent CS-induced EMT possibly through HIF-1α/TGF-β1/Smad3 signaling pathway in mice. This study suggests HIF1-α could be a potential intervention target for COPD prevention and treatment, especially for EMT in CS-induced COPD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1665-1678"},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12108966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144163188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Codelists to Identify Chronic Bronchitis and Emphysema in Routine Electronic Healthcare Record Data and Derivation of a Standardized Codelist for Future Research.","authors":"Harley Hiu Yung Kwok, Georgie May Massen, Alexander J Adamson, Constantinos Kallis, Adam Lahmami, Yaqoob Abbas Sheikh, Mohammed Hafzalla Elhag Elseddig, Nabaz Mutabchi, Jennifer Kathleen Quint","doi":"10.2147/COPD.S501421","DOIUrl":"10.2147/COPD.S501421","url":null,"abstract":"<p><p>Medical codes and codelists are essential to identify diseases, medicines, and related events when using electronic healthcare records (EHRs) for research. As multiple codes can be used to define the same medical condition, an inconsistency of applying codes by clinicians or researchers may complicate the identification of diseases. To minimize the inconsistency of codes and increase the comparability of research findings, we sought to integrate all medical codes and codelists generated from existing studies to produce a single list of codes for both chronic bronchitis and emphysema for future research. We systematically reviewed studies, which included codes used to define chronic bronchitis and/or emphysema regardless of code systems. We searched MEDLINE, Embase, Web of Science, Scopus, CINAHL, and Global Health from 1^st January 2000 to May 2024 for relevant studies. Medical codes or codelists were identified, extracted, and compiled into single codelists for chronic bronchitis and emphysema separately based on their frequency of appearance across all included studies (PROSPERO: CRD42024529169). We identified 18 studies containing codelists, from a total of 1082 studies. Only International Classification of Disease (ICD) codes were found in studies, which defined chronic bronchitis and emphysema. Chronic bronchitis was defined as 490 and 491 in ICD-9 and J40, J41, J42, and J44 in ICD-10. Meanwhile, emphysema was defined as 492 in ICD-9 and J43 in ICD-10. Additionally, to fill the current gap, we created SNOMED CT codelists for both chronic bronchitis and emphysema, to standardize the definitions of these diseases in future studies.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1679-1691"},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12108997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144163126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight-Adjusted Waist Index as a Novel Predictor of Chronic Obstructive Pulmonary Disease: Evidence from NHANES 2013-2018.","authors":"Hongjin Wang, Weiming Chen, Feilong Guo, Zengkai Xu, Xin Luo, Jiahuang Wu, Yong Zhu, Zhisheng Wang","doi":"10.2147/COPD.S513853","DOIUrl":"10.2147/COPD.S513853","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a major global health burden. The weight-adjusted waist index (WWI), a novel adiposity metric, may improve COPD risk prediction, but its association remains underexplored.</p><p><strong>Methods: </strong>Using the National Health and Nutrition Examination Survey (NHANES) 2013-2018 data (n=15,278), we assessed the WWI-COPD relationship via multivariable logistic regression, ROC analysis, and subgroup evaluations.</p><p><strong>Results: </strong>Higher WWI tertiles correlated with elevated COPD incidence. After full adjustment, each WWI unit increase linked to 70% higher COPD risk (OR=1.70, 95% CI: 1.48-1.95). Participants in the highest quartile of WWI faced a 290% increased risk compared to the lowest quartile (OR=3.90, 95% CI: 2.60-5.86). WWI (AUC=0.707) outperformed BMI (AUC=0.525) and waist circumference (AUC=0.609) in COPD prediction. A nonlinear threshold effect emerged at WWI=12.54. Subgroup analyses confirmed robustness across demographics.</p><p><strong>Conclusion: </strong>WWI is a simple, cost-effective tool for early COPD detection, outperforming BMI and waist circumference, especially in resource-limited settings, enabling timely intervention and reducing disease burden.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1625-1638"},"PeriodicalIF":2.7,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}